April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intravitreal dexamethasone implant for diabetic macular edema : a retrospective study
Author Affiliations & Notes
  • Elsa Bensoussan
    CHU NICE ST ROCH, Nice, France
  • Pierre Gastaud
    CHU NICE ST ROCH, Nice, France
  • Stephanie Agnes Baillif
    CHU NICE ST ROCH, Nice, France
  • Footnotes
    Commercial Relationships Elsa Bensoussan, None; Pierre Gastaud, None; Stephanie Baillif, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1778. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elsa Bensoussan, Pierre Gastaud, Stephanie Agnes Baillif; Intravitreal dexamethasone implant for diabetic macular edema : a retrospective study. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1778.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the efficacy of dexamethasone 0.7mg intravitreal implant in patient with chronic diabetic macular edema (DME).

Methods: Seventeen patients charts were retrospectively reviewed. Inclusion criteria comprised patients with recalcitrant DME. The main outcome measures were best corrected visual acuity (BCVA), mean central retinal thickness (CRT) and intraocular pressure (IOP).

Results: The patients mean age was 70,7 years. Seventy five percent of the patients were pseudophakik. All the patients had received a prior treatment for DME : 94% were treated with anti-VEGF therapy and 35 % with laser photocoagulation. The pre injection mean CRT was 481μm. It improved to 339μm at month 1 and to 337μm at month 3. Mean preinjection BVCA was 0,6 logmar. Mean BCVA was 0,5 logmar at month 1 and 0,4 logmar at month 3. Three patients (18%) presented with an elevated IOP.

Conclusions: Intravitreal dexamethasone improved visual acuity and macular thickness at month 1 and month 3 after injection in patients with recalcitrant DME. Longer follow-up in necessary to state on its beneficial effect in DME.

Keywords: 505 edema • 487 corticosteroids • 585 macula/fovea  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×